Interviews

Filter
216 found

Improving malaria case management

Dr Madan Mohan Pradhan, Deputy Director Health Services, NVBDCP, Ministry of Health & Family Welfare, Odisha
The National Institute of Malaria Research and the National Vector Borne Disease Control Programme, with technical and financial support from MMV, are implementing the Comprehensive Case Management Programme in four districts of Odisha. Dr Madan Mohan Pradhan speaks about the roll-out of this programme.   
2013

Gathering evidence to guide the widespread use of new ACTs

Prof Abdoulaye Djimde, University of Science, Techniques and Technologies of Bamako, Mali
To help gather evidence to guide the optimal and widespread use of new ACTs, MMV works with partners to study how they fare in the real world. Prof. Abdoulaye Djimde talks about the WANECAM trial and what it has revealed so far. 
2013

Expanding the range of ACTs in Ghana

Dr Keziah Malm, National Malaria Control Progamme, Ghana
Artemisinin-based combination therapies (ACTs) are the current WHO-recommended standard of care for uncomplicated malaria. Dr Keziah Malm provides insight into the real-world advantages of multiple first-line ACTs, which were first instituted in Ghana in 2007. 
2013

Ian Bathurst Global Health Travel Award recipient – George Ayodo

George Ayodo, Senior Research Officer, Kenya Medical Research Institute-University of Minnesota Malaria Project, Kisumu, Kenya
The Ian Bathurst Global Health Travel Awards were presented to 12 individuals studying parasitology in disease-endemic regions, to enable their attendance at Keystone Symposia’s January 2013 Malaria meeting in New Orleans.
2013

Ian Bathurst Global Health Travel Award recipient – Simone da Silva Santos

Simone da Silva Santos, Junior researcher, Fundação Instituto Oswaldo Cruz, Rio de Janeiro, Brazil
The Ian Bathurst Global Health Travel Awards were presented to 12 individuals studying parasitology in disease-endemic regions, to enable their attendance at Keystone Symposia’s January 2013 Malaria meeting in New Orleans.
2013

Ian Bathurst Global Health Travel Award recipient – Reshma Korde Chopra

Reshma Korde Chopra, Post-doctoral Visiting Scientist, Tata Institute of Fundamental Research, Mumbai, Maharashtra, India
The Ian Bathurst Global Health Travel Awards were presented to 12 individuals studying parasitology in disease-endemic regions, to enable their attendance at Keystone Symposia’s January 2013 Malaria meeting in New Orleans.
2013

Ian Bathurst Global Health Travel Award recipient – Augustina Frimpong

Augustina Frimpong, MPhil Student, Noguchi Memorial Institute for Medical Research at the University of Ghana
The Ian Bathurst Global Health Travel Awards were presented to 12 individuals studying parasitology in disease-endemic regions, to enable their attendance at Keystone Symposia’s January 2013 Malaria meeting in New Orleans.
2013

Stopping the relapse

Dr Brice Campo, Associate Director, Drug Discovery, MMV
Our goal to eradicate malaria cannot be achieved without new anti-relapse medicines. Dr Brice Campo explains the research challenges presented by P. vivax and MMV’s discovery strategy to stop the relapse. 
2012

MMV390048: Boosting African Research

Dr Michael Witty, Member of MMV's ESAC and Project Mentor
With more than 30 years of pharmaceutical research experience, Dr Michael Witty talks about the support he provides to the project MMV390048. 
2012

OSDD powering the pipeline and changing the paradigm

Dr Tanjore Balganesh, Project Head at India's OSDD Initiative
MMV is working closely with India’s Open Source Drug Discovery malaria programme to investigate the most promising compound series, initially for blood-stage malaria. Dr Tanjore Balganesh explains how open source research is taking off in India. 
2012

New models to accelerate drug development

Mark Baker, Associate Director, Translational Medicine, MMV
Mark Baker, a clinical pharmacologist, explains two innovations that are enabling MMV to accelerate the collection and use of PK/PD data to speed the development of next-generation antimalarials. 
2012

Using evidence to guide best practice

Prof Azra C Ghani, Imperial College London, UK & Prof Fred Binka, Principal Investigator of INESS
Mathematical modelling studies suggest that using multiple first-line ACTs could yield better clinical outcomes than deploying a single ACT nationwide particularly when drug resistance or treatment failures emerge. Prof. Azra Ghani and Prof. Fred Binka discuss mathematical modelling and how gathering evidence can improve malaria treatment. 
2012

Populating the pipeline

Prof. Kelly Chibale, Cape Town Drug Discovery and Development Centre (H3-D), South Africa
With our sights firmly set on malaria elimination/ eradication, MMV’s discovery work is focused on the need for novel medicines to treat relapsing malaria and block transmission. Prof. Chibale talks about his work to discover and optimize new compounds to help populate MMV’s antimalarial drug pipeline. 
2011

Scaling up an improved treatment for severe malaria

Prof. Olugbenga A Mokuolu, Centre for International Education, University of Ilorin, Nigeria
In 2011 the WHO revised its Standard Treatment Guidelines to recommend artesunate injection as the preferred treatment for severe malaria. Prof. Olugbenga A Mokuolu explains how the guideline change was made in Nigeria and what impact it has had. 
2011

All shots on goal for a single-dose cure

Dr Fiona Macintyre, Associate Director, Translational Medicine, MMV
While ACTs are available and access to them is improving, MMV cannot rest on its laurels, but must continue to innovate and develop better medicines for uncomplicated malaria. Dr Fiona Macintyre tells us about the development plan for OZ439. 
2011

Ensuring safety of new medicines

Dr Stephan Duparc, Chief Medical Officer, MMV
Monitoring post-approval drug safety has become a matter of increasing importance, as it enables us to maximize the safe use of registered medicines. Dr Stephan Duparc explains what pharmacovigilance means for MMV. 
2011

Blocking transmission

Prof. Vicky Avery, Griffith University, Australia
In an infected patient a small proportion of parasites form gametocytes, the sexual form of the parasite. It is these gametocytes, taken up by the mosquito when she feeds, that ultimately allow the parasite to infect the next person. Prof. Vicky Avery talks about her work to develop a new late-stage gametocyte assay to identify compounds that could block the transmission of malaria. 
2011

Researching relapsing P. vivax malaria

Colonel Bagus Tjahjono, Indonesian Army Health Command, Jakarta
Although primaquine is the only approved medicine for radical cure of relapsing malaria, very little is known about how well it works in combination with other medicines that treat the blood-stage infection. Colonel Bagus Tjahjono explains the need for further research on relapsing P. vivax malaria and its treatment. 
2011

Stopping the relapse

Dr Alejandro Llanos, Universidad Peruana Cayetano Heredia, Lima, Peru
The dormant liverstage form of P. vivax, which can reactivate without warning leading to the feverish symptoms of malaria, remains a challenge to treat. Dr Alejandro Llanos talks about why there is a need for new medicines to treat relapsing malaria in Peru.
2011

Treating children suffering from malaria

Dr Jane Achan, Makerere University, Kampala, Uganda
With the exception of Coartem® Dispersible, few antimalarial medicines have been specifically formulated for children. Dr Jane Achan explains the needs on the ground for doctors treating children suffering from malaria. 
2011

Developing medicines for children

Dr Isabelle Borghini-Fuhrer Director, Clinical Development, MMV
Few antimalarial medicines have been specifically formulated to provide children with age and weight-appropriate doses in a palatable form. Dr Isabelle Borghini-Fuhrer explains the challenges in the development of medicines for children and MMV’s strategy to overcome them. 
2011

Protecting pregnant women and their babies

Dr Elizabeth Juma, National Malaria Control Programme, Kenya
Pregnancy lowers a woman’s immune response to infections and so she is four-times more likely to get malaria and twice as likely to die from it than another adult. Dr Elizabeth Juma explains Kenya's approach to protecting pregnant women from malaria. 
2011

Preventing stock-outs: SMS for Life

Mr Winna Shango, Ministry of Health and Social Welfare, Tanzania
SMS for Life uses widely available SMS technology to record antimalarial stock levels at the point-of-care. Mr Winna Shango tells us how this programme is motivating health-care workers in Tanzania. 
2011

From procurement to patients

Mrs Esnet Mwape, Pharmaceutical Regulatory Authority, Zambia
ACTs are currently the best medicines available to treat uncomplicated malaria but unfortunately many patients lack access to them. Ms Esnet Mwape explains how the medicinal products coming into Zambia are now better regulated. 
2011

Bringing all the right ingredients together

Sigma-Tau, Italy
In 2011 Eurartesim® was approved by the European Medicines Agency (EMA) – the first new European antimalarial medicine for over a decade. This is a huge achievement, and takes the medicine a step closer to the patients that so sorely need it. 
2011

The world’s first producer of WHO prequalified artesunate for injection for severe malaria

Guilin Pharmaceutical, China
Guilin Pharmaceutical has been producing intravenous (IV) artesunate for patients with severe malaria since 1987. But without WHO prequalification or stringent regulatory approval, it could not be purchased by international organizations or donor funds. 
2011

Analyzing the antimalarials market

Nettie Dzabala, College of Medicine, Malawi
The College of Medicine is an academic centre of excellence, responsive to the health needs of Malawi by training professionals, providing clinical services and medical research. MMV worked with the college to analyze the antimalarial medicines market in six districts. 
2011

OZ439: A winning network of partners

Prof. Jonathan Vennerstrom, Prof. Susan Charman & Dr Sergio Wittlin
The success of the OZ439 project can be attributed to the commitment, enthusiasm and range of scientific expertise of its partners from across the globe. Today, OZ439 is on track to potentially replace artemisinin and become a part of the much-needed one-dose cure for malaria. 
2011

Feeding the drug development pipeline through the discovery of novel chemistry

Dr Thierry Diagana, Novartis Institue for Tropical Diseases, Singapore
NITD is working in close collaboration with MMV to explore new drug discovery approaches for malaria. NITD609, if proven to be well tolerated, will be the first antimalarial not belonging to either the artemisinin or peroxide class to enter clinical efficacy studies in recent years. 
2010

Guiding the development of transmission-blocking medicines

Prof. Robert Sinden, Imperial College, London, UK
Current medicines mostly kill the malaria parasite at the blood stage, but to eradicate malaria, we need to stop the parasite being passed on to the next person via mosquitos. Imperial College London has been working with MMV to turn basic biology into knowledge to underpin the development of new antimalarials. 
2010

A weapon to counter resistance

Dr Jörg Möhrle, Head of Translational Medicine, MMV
OZ439 is a fully synthetic peroxide on track to provide not only a single-dose cure for malaria, but also a potential alternative to currently used artemisinin derivatives. Dr Jörg Möhrle explains this molecule. 
2010

A long-standing collaboration

Shin Poong Pharmaceutical, South Korea
MMV and Shin Poong have worked together since 1999 to develop Pyramax®. This new once daily, 3-day treatment for uncomplicated P. falciparum and blood stage P. vivax malaria in infants, children and adults is awaiting regulatory approval by the European Medicines Agency. 
2010

Treating patients with severe malaria

Dr Arjen Dondorp, Deputy Director and Head of Malaria Research,Mahidol–Oxford Tropical Medi-cine Research Unit, Bangkok, Thailand
MMV is using its R&D know-how, working with Guilin Pharmaceutical to achieve WHO prequalification for injectale artesunate, treatment for severe malaria. Dr Arjen Dondorp, speaks about treating patients with of severe malaria. 
2010

DHODH: Academic brain meets industrial muscle

Dr Meg Phillips, University of Texas Southwestern, USA
The enzyme DHODH is one the hottest malaria drug targets under investigation today. This project was awarded MMV’s 2010 Project of the Year in recognition of its impressive progress to rapidly bring these inhibitors towards clinical testing. Dr Meg Phillips speaks about the collaboration with MMV.
2010

Overcoming the challenges of conducting clinical trials in India

Dr Neena Valecha, The National Institute of Malaria Research, India
NIMR is India’s premier malaria research institute, carrying out studies on drug resistance, and Phase II/ III trials of new drugs. Conducting clinical trials in India is a challenge but MMV and NIMR have had a successful partnership. 
2009

Delivering good, affordable drugs to those in need

Prof. Bruno Gryseels & Prof. Umberto D’Alessandro, ITM, Belgium
ITM provides postgraduate training for medical doctors and paramedics – a number of whom are headed for central Africa. Collaboration between MMV and ITM focuses on the development and trial of new antimalarials. 
2009

Pages